CRSP – Confirmed Breakout - Squeeze Pressure Mounting - Let's GoCRISPR Therapeutics AGBATS:CRSPseedCRSP – Full Breakdown of the Short Squeeze Setup, Technicals, and Fundamentals CRISPR Therapeutics (NASDAQ: CRSP) is currently setting up one of the most compelling short squeeze and momentum continuation trades in the biotech sector. After hours on July 22, 2025, the stock is trading at 67.00, pushing through a critical resistance zone with increasing volume and strong technical confirmation. Short interest is estimated at approximately 25.5 million shares, representing between 28 and 31 percent of the float. Days to cover is between 5.8 and 9.7, which is considered high. This creates a risk zone for short sellers, especially as the stock moves higher. With the price moving above 65, many in-the-money call options are being triggered, increasing the likelihood of a gamma squeeze. This occurs when market makers must hedge their exposure by buying more shares, driving the price up further. Open interest on call options has been building over the past month, particularly at the 65, 70, and 75 strike prices for the August 1 and August 16 expirations. October calls also show heavy volume. The August 16 70 call recently had over 1700 open contracts with more than 4400 contracts traded in a single session, indicating aggressive positioning. On the weekly chart, price has now broken above 66.50, a major resistance zone. RSI is above 73, signaling strong momentum. The MACD has crossed bullish with rising histogram bars. The 50-week simple moving average sits around 72 to 73, marking the next area of resistance. Price is now trading above the 10, 20, and 50-week moving averages and has broken out from the previous Darvas Box range centered around 60.88. CRSP is expected to report earnings around August 7 to August 12, 2025. In the previous quarter, the company reported a loss of 1.58 per share, missing expectations. Current estimates for Q2 range from negative 1.78 to negative 0.93, with a consensus near negative 1.40. Investors will be watching closely for updates on CRISPR’s gene therapy pipeline, especially the CTX001 program and oncology candidates. A positive earnings surprise or encouraging pipeline update could further drive upward price movement. CRISPR Therapeutics focuses on developing gene-editing therapies based on CRISPR-Cas9. Key programs include CTX001 for sickle cell disease and beta thalassemia, CAR-T therapies for cancer, and regenerative medicine applications. The company has a strong cash position and continues to invest heavily in research and development. Key support levels include 60.88 and 58.50. Immediate resistance is now 67.00, with the next target range between 72.50 and 76.00. If the short squeeze intensifies, a stretch target of 86.00 to 91.00 is possible. The all-time high for the stock is 169.76, reached in early 2021. This setup includes a confirmed technical breakout, high short interest, heavy call option flow, and an upcoming earnings catalyst. The stock is now in play, and if it holds above 67.00, further upside pressure could continue into the August earnings release. This is a live squeeze and continuation setup with both technical and fundamental tailwinds.